Wedbush analyst Michael Piccolo on Thursday reaffirmed a Neutral rating for STAAR Surgical (STAA) but raised the 12-month price target to $26 from $21. Michael Piccolo said, "While we are increasing our price target, we maintain our NEUTRAL rating as we see the risk/reward balanced at current levels." STAAR Surgical offers an implantable collamer lens product family comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for refractive surgery to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. The price target revision follows STAAR Surgical's first-quarter preliminary revenue update, which exceeded $90 million, up above 110% from $42.6 million in the first quarter of 2025. This was primarily driven by a China-based sales rebound that sharply increased after the revenue dip in the first quarter of 2025, as distributors worked through excess inventory. Michael Piccolo said, "If China Rebounds, STAAR is positioned to shine", and "We believe that the China-driven revenue collapse likely represents a temporary headwind rather than structural demand destruction." The analyst now estimates that China will generate approximately $144.4 million in revenue for the full year 2026; meanwhile, the estimate for other regions remains unchanged. The three main reasons cited by the analyst for raising the price target are: Their increased revenue estimates for the company's full-year 2026; a heavier weighting of the bull case scenario, from 25% to 40% probability; and an increase in the bear case scenario valuation, from $12 to $15 per share. STAA has traded between $14.69 and $30.81 over the last year. The stock closed Wednesday's trade at $20.88, down 1%. STAA is currently trading at $26.10, up 25%. For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.